​

Blueprint Medicines (BPMC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BPMC Stock Forecast

Blueprint Medicines (BPMC) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $127.00, with a high of $155.00 and a low of $88.00. This represents a 11.09% increase from the last price of $114.32.

$85 $99 $113 $127 $141 $155 High: $155 Avg: $127 Low: $88 Last Closed Price: $114.32

BPMC Stock Rating

Blueprint Medicines stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (64.29%), 5 Hold (35.71%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 5 9 Strong Sell Sell Hold Buy Strong Buy

BPMC Forecast vs Benchmarks

TypeNameUpside
StockBlueprint Medicines11.09%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-19
Avg Price Target-$135.00$119.33
Last Closing Price$114.32$114.32$114.32
Upside/Downside-18.09%4.38%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 255951-20
Dec, 245951-20
Nov, 245951-20
Oct, 247951123
Sep, 247941122
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Ami FadiaNeedham$135.00$89.2451.28%18.09%
Oct 24, 2024David DaiUBS$88.00$84.404.27%-23.02%
Sep 19, 2024Bradley CaninoStifel Nicolaus$155.00$90.9470.44%35.58%
Aug 01, 2024Matthew BieglerOppenheimer$130.00$102.0527.39%13.72%
Jul 29, 2024Peter LawsonBarclays$105.00$112.19-6.41%-8.15%
Jul 08, 2024Matthew BieglerOppenheimer$125.00$116.557.25%9.34%
May 06, 2024Andrew BerensLeerink Partners$97.00$107.19-9.51%-15.15%
May 03, 2024Christopher RaymondRaymond James$104.00$106.29-2.15%-9.03%
May 03, 2024Andrew FeinH.C. Wainwright$135.00$107.0026.17%18.09%
Dec 14, 2022Needham$60.00$46.6028.76%-47.52%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024CitigroupBuyBuyhold
Oct 31, 2024NeedhamBuyBuyhold
Oct 30, 2024OppenheimerOutperformOutperformhold
Oct 24, 2024UBSBuyBuyhold
Oct 24, 2024UBSNeutralinitialise
Aug 01, 2024OppenheimerOutperformOutperformhold
Jul 29, 2024StephensBuyBuyhold
Jul 29, 2024BarclaysEqual-WeightEqual-Weighthold
Jul 12, 2024Morgan StanleyEqual-WeightEqual-Weighthold
Jul 07, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-15 $-10 $-5 $0 $5 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.76$-11.01$-9.35$-8.50-----
Avg Forecast$5.49$-6.27$-9.35$-8.58$-0.98$-0.88$1.80$4.23$6.00
High Forecast$4.87$-7.77$-10.07$-8.80$-1.28$-1.80$-1.25$1.07$5.44
Low Forecast$6.80$-5.56$-8.07$-8.33$-0.76$0.21$5.79$8.72$6.65
Surprise %4.92%75.60%--0.93%-----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$793.74M$180.08M$204.04M$249.38M-----
Avg Forecast$788.84M$176.15M$199.35M$245.11M$509.01M$725.96M$963.91M$1.21B$1.39B
High Forecast$719.96M$160.77M$178.49M$235.49M$503.40M$676.21M$963.64M$1.21B$1.29B
Low Forecast$933.98M$208.56M$211.25M$255.78M$522.14M$789.29M$964.17M$1.21B$1.51B
Surprise %0.62%2.23%2.35%1.74%-----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$313.88M$-644.09M$-557.52M$-506.98M-----
Avg Forecast$71.45M$-494.28M$-517.62M$-506.98M$-61.93M$-74.90M$103.91M$262.80M$363.24M
High Forecast$-68.91M$-593.13M$-621.15M$-608.38M$-77.65M$-108.71M$-75.65M$64.79M$329.55M
Low Forecast$211.81M$-395.42M$-414.10M$-405.59M$-46.22M$12.79M$350.78M$528.05M$402.96M
Surprise %339.30%30.31%7.71%------

BPMC Forecast FAQ

Is Blueprint Medicines stock a buy?

Blueprint Medicines stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Blueprint Medicines is a favorable investment for most analysts.

What is Blueprint Medicines's price target?

Blueprint Medicines's price target, set by 14 Wall Street analysts, averages $127 over the next 12 months. The price target range spans from $88 at the low end to $155 at the high end, suggesting a potential 11.09% change from the previous close price of $114.32.

How does Blueprint Medicines stock forecast compare to the average forecast of its sector, industry, and investment themes?

Blueprint Medicines stock forecast shows a 11.09% upside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Blueprint Medicines over the past three months?

  • January 2025: 25.00% Strong Buy, 45.00% Buy, 25.00% Hold, 5.00% Sell, 0% Strong Sell.
  • December 2024: 25.00% Strong Buy, 45.00% Buy, 25.00% Hold, 5.00% Sell, 0% Strong Sell.
  • November 2024: 25.00% Strong Buy, 45.00% Buy, 25.00% Hold, 5.00% Sell, 0% Strong Sell.

What is Blueprint Medicines’s EPS forecast?

Blueprint Medicines's average annual EPS forecast for its fiscal year ending in December is -0.98 for 2024, a -88.47% decrease from the reported $-8.5 in 2023. The prediction for 2025 is $-0.88, $1.8 for 2026, $4.23 for 2027, and $6 for 2028.

What is Blueprint Medicines’s revenue forecast?

Blueprint Medicines's average annual revenue forecast for its fiscal year ending in December is $509.01M for 2024, a 104.11% increase from the reported $249.38M in 2023. The forecast for 2025 is $725.96M, $963.91M for 2026, $1.21B for 2027, and $1.39B for 2028.

What is Blueprint Medicines’s net income forecast?

For its fiscal year ending in December, Blueprint Medicines's average annual net income forecast is $-61.932M for 2024, reflecting a -87.78% decrease from the reported $-507M in 2023. The projection for 2025 is $-74.901M, $103.91M for 2026, $262.8M for 2027, and $363.24M for 2028.